Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Food Hypersensitivity | 7 | 2022 | 154 | 2.030 |
Why?
|
| Immunologic Deficiency Syndromes | 3 | 2021 | 205 | 1.200 |
Why?
|
| Arthropod Venoms | 1 | 2023 | 5 | 0.860 |
Why?
|
| Ants | 1 | 2023 | 8 | 0.860 |
Why?
|
| Insect Bites and Stings | 1 | 2023 | 38 | 0.830 |
Why?
|
| Anaphylaxis | 2 | 2023 | 82 | 0.830 |
Why?
|
| Allergens | 3 | 2022 | 252 | 0.660 |
Why?
|
| Asthma | 4 | 2018 | 756 | 0.610 |
Why?
|
| Hypersensitivity | 2 | 2018 | 185 | 0.600 |
Why?
|
| Nut and Peanut Hypersensitivity | 1 | 2016 | 2 | 0.540 |
Why?
|
| Sesamum | 1 | 2016 | 3 | 0.540 |
Why?
|
| Nut Hypersensitivity | 1 | 2016 | 7 | 0.530 |
Why?
|
| Desensitization, Immunologic | 1 | 2018 | 103 | 0.530 |
Why?
|
| Arachis | 1 | 2016 | 74 | 0.500 |
Why?
|
| Peanut Hypersensitivity | 1 | 2016 | 75 | 0.480 |
Why?
|
| Mast Cells | 3 | 2021 | 78 | 0.450 |
Why?
|
| Immunoglobulin E | 4 | 2022 | 162 | 0.400 |
Why?
|
| Tryptases | 2 | 2021 | 20 | 0.350 |
Why?
|
| Anti-Allergic Agents | 2 | 2021 | 27 | 0.320 |
Why?
|
| Arylsulfonates | 1 | 2007 | 3 | 0.280 |
Why?
|
| Sulfonium Compounds | 1 | 2007 | 4 | 0.280 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2007 | 112 | 0.250 |
Why?
|
| Monocytes | 1 | 2007 | 345 | 0.240 |
Why?
|
| Dendritic Cells | 1 | 2007 | 414 | 0.230 |
Why?
|
| Child, Preschool | 8 | 2023 | 14154 | 0.220 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2004 | 139 | 0.220 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2004 | 75 | 0.210 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2022 | 66 | 0.190 |
Why?
|
| Urticaria | 1 | 2021 | 21 | 0.180 |
Why?
|
| Humans | 21 | 2023 | 125295 | 0.180 |
Why?
|
| Skin Tests | 2 | 2018 | 78 | 0.170 |
Why?
|
| Mastocytosis, Systemic | 1 | 2020 | 7 | 0.170 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2020 | 9 | 0.170 |
Why?
|
| Antigens, Dermatophagoides | 2 | 2018 | 9 | 0.170 |
Why?
|
| Metabolic Diseases | 1 | 2021 | 130 | 0.170 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2021 | 236 | 0.160 |
Why?
|
| Cell Differentiation | 1 | 2007 | 1909 | 0.160 |
Why?
|
| Young Adult | 3 | 2018 | 9062 | 0.160 |
Why?
|
| Adolescent | 6 | 2021 | 19427 | 0.150 |
Why?
|
| Artemia | 1 | 2018 | 3 | 0.150 |
Why?
|
| Malnutrition | 1 | 2021 | 209 | 0.150 |
Why?
|
| Pyroglyphidae | 1 | 2018 | 9 | 0.150 |
Why?
|
| Animals | 4 | 2023 | 34320 | 0.140 |
Why?
|
| Cross Reactions | 1 | 2018 | 192 | 0.140 |
Why?
|
| Wounds and Injuries | 1 | 2021 | 371 | 0.140 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2021 | 442 | 0.140 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 645 | 0.140 |
Why?
|
| Leukemia | 1 | 2020 | 367 | 0.130 |
Why?
|
| Bixaceae | 1 | 2016 | 2 | 0.130 |
Why?
|
| ROC Curve | 1 | 2018 | 572 | 0.130 |
Why?
|
| Seeds | 1 | 2016 | 42 | 0.130 |
Why?
|
| Administration, Oral | 1 | 2018 | 683 | 0.130 |
Why?
|
| Child | 6 | 2022 | 24625 | 0.130 |
Why?
|
| Fatty Acids, Monounsaturated | 2 | 2006 | 47 | 0.120 |
Why?
|
| Fluticasone-Salmeterol Drug Combination | 1 | 2015 | 8 | 0.120 |
Why?
|
| Carotenoids | 1 | 2016 | 75 | 0.120 |
Why?
|
| Cushing Syndrome | 1 | 2015 | 15 | 0.120 |
Why?
|
| Budesonide | 1 | 2015 | 18 | 0.120 |
Why?
|
| Itraconazole | 1 | 2015 | 25 | 0.120 |
Why?
|
| Histoplasma | 1 | 2015 | 31 | 0.120 |
Why?
|
| Protein-Losing Enteropathies | 1 | 2015 | 19 | 0.120 |
Why?
|
| Bronchiectasis | 1 | 2015 | 22 | 0.120 |
Why?
|
| Histoplasmosis | 1 | 2015 | 48 | 0.120 |
Why?
|
| Plant Extracts | 1 | 2016 | 119 | 0.120 |
Why?
|
| Pollen | 1 | 2015 | 46 | 0.120 |
Why?
|
| Adult | 6 | 2018 | 29514 | 0.120 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2015 | 106 | 0.120 |
Why?
|
| Indoles | 2 | 2006 | 191 | 0.120 |
Why?
|
| Penaeidae | 1 | 2004 | 4 | 0.110 |
Why?
|
| Male | 9 | 2021 | 61527 | 0.110 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2004 | 16 | 0.110 |
Why?
|
| Shellfish | 1 | 2004 | 31 | 0.110 |
Why?
|
| Respiratory Mucosa | 1 | 2004 | 91 | 0.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2007 | 471 | 0.110 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 2057 | 0.110 |
Why?
|
| Infant | 3 | 2023 | 12606 | 0.100 |
Why?
|
| Female | 8 | 2022 | 66789 | 0.100 |
Why?
|
| Middle Aged | 5 | 2018 | 26726 | 0.100 |
Why?
|
| Cytomegalovirus Infections | 1 | 2004 | 223 | 0.100 |
Why?
|
| Biomarkers | 1 | 2020 | 3105 | 0.090 |
Why?
|
| Chemokine CCL17 | 2 | 2007 | 9 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 1592 | 0.090 |
Why?
|
| Chemokines, CC | 2 | 2007 | 28 | 0.090 |
Why?
|
| Interleukin-5 | 2 | 2007 | 43 | 0.090 |
Why?
|
| HIV Infections | 1 | 2021 | 1896 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2007 | 3313 | 0.080 |
Why?
|
| Aged | 2 | 2018 | 19704 | 0.080 |
Why?
|
| Prevalence | 1 | 2014 | 2467 | 0.070 |
Why?
|
| Interferon-gamma | 2 | 2007 | 505 | 0.070 |
Why?
|
| Cell Survival | 2 | 2007 | 821 | 0.070 |
Why?
|
| Lymphocyte Activation | 2 | 2007 | 700 | 0.070 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2007 | 14 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 1097 | 0.070 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2007 | 69 | 0.070 |
Why?
|
| Interleukin-4 | 1 | 2007 | 140 | 0.070 |
Why?
|
| Interleukin-12 | 1 | 2007 | 116 | 0.070 |
Why?
|
| Neoplasms | 1 | 2021 | 2794 | 0.070 |
Why?
|
| Coculture Techniques | 1 | 2007 | 228 | 0.070 |
Why?
|
| Lung | 1 | 2004 | 1491 | 0.070 |
Why?
|
| Interleukin-10 | 1 | 2007 | 174 | 0.060 |
Why?
|
| Chemokines | 1 | 2006 | 134 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2007 | 430 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 325 | 0.060 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2004 | 38 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2007 | 3044 | 0.060 |
Why?
|
| Statistics, Nonparametric | 2 | 2004 | 433 | 0.050 |
Why?
|
| Gulf of Mexico | 1 | 2022 | 4 | 0.050 |
Why?
|
| Respiratory Burst | 1 | 2022 | 10 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2004 | 2907 | 0.050 |
Why?
|
| RNA Splice Sites | 1 | 2022 | 90 | 0.050 |
Why?
|
| NADPH Oxidases | 1 | 2022 | 112 | 0.050 |
Why?
|
| Cetirizine | 1 | 2021 | 4 | 0.050 |
Why?
|
| Mastocytosis | 1 | 2021 | 7 | 0.050 |
Why?
|
| Twins, Monozygotic | 1 | 2021 | 117 | 0.040 |
Why?
|
| Environment | 1 | 2021 | 142 | 0.040 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2021 | 118 | 0.040 |
Why?
|
| Cytokines | 1 | 2006 | 1291 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2007 | 2373 | 0.040 |
Why?
|
| United States | 1 | 2014 | 10910 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 495 | 0.040 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 730 | 0.040 |
Why?
|
| Apoptosis | 1 | 2005 | 1818 | 0.040 |
Why?
|
| Chimerism | 1 | 2015 | 28 | 0.030 |
Why?
|
| Photomicrography | 1 | 2004 | 12 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2015 | 130 | 0.030 |
Why?
|
| Airway Resistance | 1 | 2004 | 36 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2015 | 254 | 0.030 |
Why?
|
| Basement Membrane | 1 | 2004 | 48 | 0.030 |
Why?
|
| Cell Degranulation | 1 | 2004 | 29 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 1901 | 0.030 |
Why?
|
| Autopsy | 1 | 2004 | 110 | 0.030 |
Why?
|
| Radioallergosorbent Test | 1 | 2004 | 7 | 0.030 |
Why?
|
| Cell Count | 1 | 2004 | 252 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 228 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2004 | 309 | 0.030 |
Why?
|
| China | 1 | 2004 | 246 | 0.030 |
Why?
|
| Observer Variation | 1 | 2004 | 300 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2004 | 212 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1270 | 0.030 |
Why?
|
| Reference Values | 1 | 2004 | 719 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 2004 | 269 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2004 | 478 | 0.030 |
Why?
|
| Weight Gain | 1 | 2015 | 400 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2004 | 1017 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 825 | 0.020 |
Why?
|
| Viral Load | 1 | 2004 | 388 | 0.020 |
Why?
|
| Pedigree | 1 | 2015 | 1610 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2004 | 1111 | 0.020 |
Why?
|
| Prognosis | 1 | 2020 | 4686 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 1704 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 3176 | 0.020 |
Why?
|
| Phenotype | 1 | 2020 | 4271 | 0.020 |
Why?
|
| Protein Binding | 1 | 2004 | 1757 | 0.020 |
Why?
|
| Proteins | 1 | 2004 | 1039 | 0.020 |
Why?
|
| Phytohemagglutinins | 1 | 2006 | 13 | 0.020 |
Why?
|
| Receptors, CCR4 | 1 | 2006 | 7 | 0.020 |
Why?
|
| Mevalonic Acid | 1 | 2006 | 19 | 0.020 |
Why?
|
| Receptors, CXCR3 | 1 | 2006 | 21 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2006 | 45 | 0.020 |
Why?
|
| Chemokines, CXC | 1 | 2006 | 37 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2006 | 108 | 0.020 |
Why?
|
| Chemokine CXCL10 | 1 | 2006 | 53 | 0.020 |
Why?
|
| Phorbol 12,13-Dibutyrate | 1 | 2005 | 8 | 0.020 |
Why?
|
| Ionomycin | 1 | 2005 | 19 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2005 | 51 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2005 | 72 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2005 | 91 | 0.020 |
Why?
|
| Th2 Cells | 1 | 2006 | 185 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2006 | 153 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 173 | 0.010 |
Why?
|
| Caspases | 1 | 2005 | 162 | 0.010 |
Why?
|
| Cell Division | 1 | 2006 | 780 | 0.010 |
Why?
|
| Antibodies | 1 | 2005 | 374 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2005 | 692 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2015 | 8274 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 2757 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2004 | 12280 | 0.010 |
Why?
|